1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Verrica’s Anticancer Efforts Kick Off With Promising Early Phase II BCC Data

In Handful Of Patients

 
• By Ayisha Sharma

The US firm’s oncolytic peptide candidate, VP-315, has shown tumor clearance in a Phase II basal cell carcinoma trial, marking a positive start for its plans to expand from non-malignant dermatology to skin cancer.  

biopsy of basal cell carcinoma cell, cancer
There Are More Than Five Million New Cases Of BCC In The US Every Year • Source: Shutterstock
Key Takeaways:

  • Of six patients administered with the therapy, four had complete tumor clearance at 49 days.

  • Verrica is adding more sites to part two of the trial to hasten the asset’s development.

  • Last month, the firm’s drug-device combination Ycanth was approved for molluscum.

Verrica Pharmaceuticals, Inc.’ first-in-class oncolytic peptide asset, VP-315, has shown efficacy signals in a Phase II trial in patients with basal cell carcinoma (BCC) just a month after the...

BCC is the most common form of skin cancer with an estimated 5.4 million new cases diagnosed in the US each year. VP-315 is designed to induce immunogenic cell death...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Angelini Advances Brain Health Ambitions With GRIN Pact

 
• By Kevin Grogan

The Italian drugmaker gets rights to Phase III-ready asset radiprodil.

Sweden’s Hansa Slims Down Ahead of Key Readouts

 
• By Kevin Grogan

New CEO Renée Aguiar-Lucander is marking her mark.

Gilead Ready To Go After Hepatitis D Again

 
• By Joseph Haas

Following an FDA complete response in 2022, Gilead is getting ready to refile bulevirtide for hepatitis D. The drug already is approved in the EU, UK and elsewhere.

Progress In The Effort To Improve Outcomes In SCLC

 
• By Jessica Merrill

Several drug makers are working to bring new advances to small-cell lung cancer, a fast-growing cancer with limited treatment options.

More from R&D

Pipeline Watch: 12 Approvals And 26 Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

GSK’s Nucala Set For Dupixent Face-Off After FDA COPD Nod

 
• By Kevin Grogan

The UK major's asthma drug gets a key expanded approval.

Merus Bispecific Impresses In Head And Neck Cancer

 
• By Andrew McConaghie

Updated Phase II results from petosemtamab have impressed ahead of ASCO, outshining Keytruda monotherapy and its bispecific rival from Bicara.